Standout Papers

ChEMBL: a large-scale bioactivity database for drug discovery 2006 2026 2012 2019 2.8k
  1. ChEMBL: a large-scale bioactivity database for drug discovery (2011)
    Anna Gaulton, Louisa J. Bellis et al. Nucleic Acids Research
  2. How many drug targets are there? (2006)
    John P. Overington, Bissan Al‐Lazikani et al. Nature Reviews Drug Discovery
  3. The ChEMBL database in 2017 (2016)
    Anna Gaulton, Anne Hersey et al. Nucleic Acids Research
  4. A comprehensive map of molecular drug targets (2016)
    Rita Santos, Oleg Ursu et al. Nature Reviews Drug Discovery
  5. The ChEMBL bioactivity database: an update (2013)
    A. Patrícia Bento, Anna Gaulton et al. Nucleic Acids Research
  6. The druggable genome and support for target identification and validation in drug development (2017)
    Chris Finan, Anna Gaulton et al. Science Translational Medicine
  7. ChEMBL web services: streamlining access to drug discovery data and utilities (2015)
    Mark Davies, Michał Nowotka et al. Nucleic Acids Research

Immediate Impact

29 by Nobel laureates 42 from Science/Nature 89 standout
Sub-graph 1 of 21

Citing Papers

Empowering biomedical discovery with AI agents
2024 Standout
Refining the impact of genetic evidence on clinical success
2024 StandoutNature
6 intermediate papers

Works of John P. Overington being referenced

Improving the odds of drug development success through human genomics: modelling study
2019
A comprehensive map of molecular drug targets
2016 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
John P. Overington 11434 6697 2289 95 16.1k
Woody Sherman 9955 5373 1700 98 16.2k
John J. Irwin 12892 10864 2632 87 19.3k
Andrew R. Leach 8761 6574 1976 82 14.2k
Robert C. Glen 8071 5852 1556 194 14.1k
Robert Abel 11054 4095 2820 72 15.6k
Tudor I. Oprea 9155 6422 1210 240 17.9k
Andrew L. Hopkins 8878 4760 764 61 13.7k
Christopher W. Murray 8248 5775 1880 94 13.4k
Stephen H. Bryant 13701 4623 2772 152 20.7k
Anne Hersey 6428 6138 1526 49 11.2k

All Works

Loading papers...

Rankless by CCL
2026